文献速递淋巴瘤

PD-1抑制剂联合GVD方案对比GVD方案二线治疗复发难治性经典型霍奇金淋巴瘤

Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2021-10-07

该回顾性研究纳入103例一线治疗失败的经典型霍奇金淋巴瘤患者,比较PD-1抑制剂联合GVD方案(27例)与GVD方案(76例)的疗效与毒性。低危国际预后评分亚组及PD-1巩固治疗者获益更明显,联合方案毒性总体可比,但甲状腺功能减退和自身免疫性肺炎发生率更高且可控。

要点

  • PD-1抑制剂联合GVD方案二线治疗cHL的完全缓解率有更高趋势,无事件生存期显著更优。
  • 低危第二线国际预后评分患者加用PD-1抑制剂获益更明显。
  • 联合方案毒性总体与GVD相当,但甲状腺功能减退和免疫性肺炎发生率更高且可控。

核心结论

  • PD-1抑制剂联合GVD方案可能是复发难治性经典型霍奇金淋巴瘤潜在有效的二线治疗。

研究设计与样本

  • 回顾性研究,共纳入103例一线治疗失败的经典型霍奇金淋巴瘤患者,GVD+PD-1组27例,GVD组76例,疗效评估基于PET。

主要发现

  • GVD+PD-1方案毒性总体与GVD方案相当,但甲状腺功能减退和自身免疫性肺炎发生率更高,均可管理。

临床怎么用

  • 对于一线治疗失败的经典型霍奇金淋巴瘤患者,可考虑PD-1抑制剂联合GVD方案作为二线治疗选择。
  • 治疗中需关注甲状腺功能减退和自身免疫性肺炎,并进行相应监测和管理。

局限性

  • 本研究为回顾性研究,样本量有限,结果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with classical Hodgkin lymphoma (cHL) who do not achieve complete remission (CR) after second-line chemotherapy have poor clinical outcomes. Besides, conventional salvage chemotherapy regimens have an unsatisfactory CR rate. The present retrospective study reports the efficacy and toxicity of the GVD (gemcitabine, vinorelbine, liposomal doxorubicin) regimen with or without programmed cell death 1 (PD-1) inhibitor for patients with cHL who failed first-line treatment. A total of 103 patients with cHL (GVD+PD-1 group, n = 27; GVD group, n = 76) with response assessment based on positron emission tomography were included. The GVD+PD-1 group tended to have a higher CR rate than GVD group (85·2% vs. 65·8%, P = 0·057) and had a better event-free survival (EFS) (P = 0·034). Subgroup analysis showed that patients with low-risk second-line International Prognostic Score might benefit from the addition of PD-1 inhibitor (GVD+PD-1 vs. GVD, 100·0% vs. 64·7%, P = 0·028) and had better EFS than GVD alone (P = 0·016). Further analysis demonstrated that PD-1 consolidation therapy might provide an EFS benefit (P = 0·007). The toxicity of the GVD+PD-1 regimen was comparable to the GVD regimen, except for higher rates of hypothyroidism and autoimmune pneumonitis, which were manageable. In conclusion, combining a PD-1 inhibitor with a GVD regimen could be a potentially effective second-line therapy for patients with cHL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang YC, Wang JN, Ma SY, et al. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma. Br J Haematol. 2021. PMID: 34618912. doi:10.1111/bjh.17849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。